OBJECTIVE To synthesize the cost-effectiveness (CE) of interventions to prevent and control
diabetes, its complications, and comorbidities. RESEARCH DESIGN AND METHODS We …

Background Chronic kidney disease (CKD) is a progressive condition that leads to
irreversible damage to the kidneys and is associated with an increased incidence of …

The International Diabetes Federation (IDF) and the International Society of Nephrology
(ISN) have developed this policy brief to target advocates, healthcare professionals and …

Background Structured comparison of pharmacoeconomic analyses for ACEIs and ARBs in
patients with type 2 diabetic nephropathy is still lacking. This review aims to systematically …

The International Diabetes Federation (IDF) and the International Society of Nephrology
(ISN) have developed this policy brief to target advocates, healthcare professionals and …

Increases in the prevalence and economic impact of diabetes have resulted in greater
perceived importance and availability of good quality information on the economics of …

Background: Diabetes is a leading cause of end stage renal disease (ESRD), which impacts
on treatment costs and patients' quality of life. Microalbuminuria screening in patients with …

Introduction As novel therapies for chronic kidney disease (CKD) in type 2 diabetes mellitus
(T2DM) become available, their long-term benefits should be evaluated using CKD …

The current screening method for diabetic nephropathy (DN) is based upon the detection of
urinary albumin and the decline of estimated glomerular filtration rate, which occurs …

University of Groningen Use of real-world evidence in pharmacoeconomic analysis Huang,
Yunyu Page 1 University of Groningen Use of real-world evidence in pharmacoeconomic …